Oppenheimer analyst Leland Gershell maintained a Hold rating on Alnylam Pharmaceuticals on Friday, setting a price target of $171, which is approximately 3.40% above the present share price of $165.38.
Gershell expects Alnylam Pharmaceuticals to post earnings per share (EPS) of -$2.18 for the first quarter of 2021.
The current consensus among 13 TipRanks analysts is for a Moderate Buy rating of shares in Alnylam Pharma (NASDAQ:ALNY), with an average price target of $167.23.
The analysts price targets range from a high of $225 to a low of $93.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $125.85 million and a net profit of -$225.2 million. The company's market cap is $19.21 billion.
According to TipRanks.com, Oppenheimer analyst Leland Gershell is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 26.1% and a 55.00% success rate.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp (OTC:SHCAY) on June 14, 2002 and is headquartered in Cambridge, MA.